Search Results
Your search for texas a matches 2595 pages
Showing 901 - 950National Comprehensive Cancer Network Celebrates Its 25th Year
It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...
SABCS Teams With Tigerlily Foundation for #InclusionPledge to Improve Health-Care Equity for Black Women
In the midst of a global pandemic, while the entire country grapples with recent events highlighting systemic racism, national breast cancer patient organizations are committing to an unprecedented health-equity initiative that focuses on diversity and inclusion. As a result, the San Antonio Breast ...
Novel Treatments Emerge for Patients With Lower-Risk Myelodysplastic Syndromes
Patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on red blood cell transfusions have limited options, especially if they are no longer responding to erythropoiesis-stimulating agents. Research presented during the virtual edition of the 25th European Hematology Association ...
Study Finds Lack of Parental Intent to Initiate and Complete HPV Vaccination in the United States
Study results documenting parental hesitancy to begin and complete their child's human papillomavirus (HPV) vaccine series were published by Sonawane et al in The Lancet Public Health. The Centers for Disease Control and Prevention recommends a two-dose HPV vaccination regimen for children if the...
Does Adjuvant Chemotherapy Improve Survival Among Older Patients With ER-Positive, Node-Positive Breast Cancer and Multiple Comorbidities?
In a retrospective cohort study reported in JAMA Oncology, Tamirisa et al found evidence that adjuvant chemotherapy was associated with improved survival among patients age ≥ 70 years with estrogen receptor (ER)-positive, HER2-negative, node-positive breast cancer and multiple comorbidities. Study...
Neuroleptic Strategies for Improving Terminal Agitation in Patients With Cancer and Delirium
In a small single-center randomized trial reported in The Lancet Oncology, David Hui, MD, MS, MSc, and colleagues found that increasing haloperidol dose, rotating to chlorpromazine, and combining haloperidol and chlorpromazine each appeared to improve refractory agitation in patients with terminal...
New Guideline for Locally Advanced Esophageal Cancer Supports Multimodality Therapy and Multidisciplinary Treatment
ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment.1 An expert panel developed the guideline based on 17...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Expert Point of View: John D. Minna, MD
John D. Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research at The University of Texas Southwestern Medical Center, Dallas, was enthusiastic about this approach. “When I first heard about it, I was so...
First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer
In a single-institution retrospective study reported in JAMA Surgery, Perri et al found that first-line FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a higher response rate and subsequent pancreatectomy vs gemcitabine plus nab-paclitaxel in patients with...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Christopher I. Amos, PhD, Receives Award for Research Excellence in Cancer Epidemiology and Prevention
The American Association for Cancer Research (AACR) is honoring Christopher I. Amos, PhD, with the 2020 AACR–American Cancer Society (ACS) Award for Research Excellence in Cancer Epidemiology and Prevention. Dr. Amos, the Selzman Endowed Professor, Director of the Institute for Clinical and...
Beth Levine, MD, Renowned Doctor and Researcher in the Field of Autophagy, Dies at 60
Beth Levine, MD, Professor of Internal Medicine and Microbiology, Director of the Center for Autophagy Research, and Charles Cameron Sprague Distinguished Chair in Biomedical Sciences at The University of Texas Southwestern Medical Center (UT Southwestern), and an investigator at the Howard Hughes ...
Oscar Colegio,MD, PhD, Expert on Skin Cancers Linked to Immunodeficiencies, Dies at 47
Oscar Colegio, MD, PhD, the Lawrence P. & Joan Castellani Family Endowed Chair in Dermatology at Roswell Park Comprehensive Cancer Center, Buffalo, New York, died unexpectedly on June 13, 2020, at a family residence in Connecticut. He was 47. Dr. Colegio had relocated to Buffalo when he was...
NCCN Working Group Policy Recommendations
As the 21st Century Cures Act approaches its 4th anniversary, the National Comprehensive Cancer Network® (NCCN®) convened a working group made up of multidisciplinary experts from across the country to analyze current issues related to the 21st Century Cures Act and to develop recommendations for ...
AACR Recognizes Achievements of Three Cancer Researchers
The American Association for Cancer Research (AACR) is honoring three clinical cancer researchers for their outstanding achievements. Jedd D. Wolchok, MD, PhD, FASCO, will receive the 2020 AACR–Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. Lisa A. Newman, MD,...
AACR Recognizes New 2019–2020 Research Grantees
The American Association for Cancer Research (AACR) has announced its newest class of grant recipients. Fellowships The 2019 Anna D. Barker Fellowship in Basic Cancer Research was awarded to Chaoyun Pan, PhD, of Emory University, Atlanta, and Conghui Yao, PhD, of Harvard Medical School, Cambridge....
A New Website Offers Support for Adolescent and Young Adults With Cancer During the COVID-19 Pandemic
Although the full impact of the COVID-19 pandemic on patients with cancer is still being evaluated, data from several studies show that in comparison with people who do not have cancer, those who do generally experience a higher risk of severe events including admittance to the intensive care unit, ...
2020 ASCO Presidential Address Focuses on ‘Unite and Conquer: Accelerating Progress Together’
The world is grappling with a pandemic and we are all adjusting to a new reality. Fewer handshakes, more masks. Fewer hugs, more fear. COVID-19 has tested us, challenged us, changed us. It’s changed the way we look, the way we work, the way we socialize. It’s changed us, but it can’t stop us. It...
GI-Related Patient-Reported Outcomes in Individuals Receiving Chemoradiation for Anal Cancer
In a single-institution study reported in JCO Oncology Practice, Kouzy et al found that gastrointestinal (GI)-related patient-reported outcomes among those receiving chemoradiation for anal cancer improved vs baseline at 1 week after treatment initiation, were worse vs baseline at 5 weeks, but did...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma
In patients with metastatic urothelial carcinoma, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to findings published by Goswami et al in Science...
Novel Risk Calculator for Sentinel Node Positivity in Patients With Melanoma
As reported in the Journal of Clinical Oncology, Lo et al developed a novel risk calculator for sentinel node metastasis—the Melanoma Institute Australia Nomogram—that appears to more accurately predict risk of metastasis in patients with primary cutaneous melanoma than other commonly used risk...
Sedentary Behavior and Risk of Cancer Mortality
In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to...
Conquer Cancer Honors Early-Career Medical Professionals From Around the World
Conquer Cancer®, the ASCO Foundation honored recipients of the 2020 Medical Student Rotation for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), Long-Term International Fellowship (LIFe), and International Development and Education Awards (IDEA)...
AMA Announces New President and President-Elect
Susan R. Bailey, MD, an allergist from Fort Worth, recently took office as the 175th President of the American Medical Association (AMA), the nation’s premier physician organization. Dr. Bailey is the third consecutive woman to hold the office, a record for the AMA. In addition, the organization...
ASCO Welcomes 2020–2021 Board of Directors
ASCO is pleased to welcome the 2020–2021 Board of Directors and introduce the newly installed leaders who began their terms at the conclusion of the Annual Business Meeting on June 1, 2020. ASCO and the Board of Directors extend their sincere gratitude to the outgoing Board members whose terms...
You-Can-Do-Anything Philosophy Early in Life Inspired Breast Surgeon Laura S. Dominici, MD
Breast surgical oncologist Laura S. Dominici, MD, was born and reared in Litchfield, a small town in the southern portion of New Hampshire. “Our house was on a long dirt road, in a very rural area,” she shared. “There were only about 5,000 residents in the town. My mother was a teacher, and my dad...
Ganesh Rao, MD, Named Chair of Neurosurgery at Baylor College of Medicine
Baylor College of Medicine recently announced that Ganesh Rao, MD, has been named the new Chair of the Department of Neurosurgery. In this role, he also will hold the Marc J. Shapiro Endowed Chair at Baylor and will serve as the Neurosurgery Service Line Chief across the Catholic Health...
Survival Disparities Seen in Hispanic Patients With Blood Cancers Living Near the United States/Mexico Border
A study by Bencomo-Alvarez et al investigating the incidence and survival for Hispanic patients with hematologic malignancies living along the United States/Mexico border in El Paso, Texas, has found that those patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myeloid...
Farhad Ravandi-Kashani, MD, on Acute Myeloid Leukemia: AMG 330 in Patients With Relapsed or Refractory Disease
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity,...
Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
Talazoparib Yields No Overall Survival Benefit in EMBRACA Trial Update
The poly (ADP-ribose) polymerase inhibitor talazoparib did not improve overall survival in women with metastatic HER2-negative breast cancer and mutations in the BRCA1 and BRCA2 genes, according to new results from the phase III EMBRACA trial presented at the 2020 American Association for Cancer...
From Ecuador to Nashville to Dallas: An Early Path to a Career in Medicine for Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, is Director of the Harold C. Simmons Cancer Center and Associate Dean for Oncology Programs, UT Southwestern Medical Center (UTSW), Dallas. He is an expert in breast cancer who has authored more than 350 publications in the areas of oncogenes in breast tumors, targeted...
Expert Point of View: Padmanee Sharma, MD, PhD
Discussant of the IMbassador250 trial, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, said: “These data indicate that neither anti–PD-1/PD-L1 monotherapy or the combination of anti–PD-1/PD-L1 with enzalutamide is likely to provide improved clinical benefit ...
RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...
Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in ...
Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at ...
Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher
When oncology luminary Joyce A. O’Shaughnessy, MD, was in her early teens, her youngest sister, Teri, developed acute lymphocytic leukemia at age 5. Dr. O’Shaughnessy, the oldest of four girls, recalled that her sister’s struggle with the disease had a profound effect on her worldview. “Teri went...
Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the...
HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC). The results of the phase II trial were shared ...
Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
Martin F. Dietrich, MD, PhD, Joins Florida Cancer Institute
Florida Cancer Specialists & Research Institute of Lake Mary, Florida has announced that medical oncologist Martin F. Dietrich, MD, PhD, has joined the cancer specialty group. Dr. Dietrich is Board-certified in internal medicine and medical oncology. In his clinical practice, he addresses all...
City of Hope Welcomes Stanley Hamilton, MD, and Alexey Danilov, MD, PhD
City of Hope has announced the addition of pathologist Stanley Hamilton, MD, and researcher Alexey Danilov, MD, PhD, to the National Medical Center in Duarte, California. Dr. Hamilton is a recognized leader in pathology who helped develop pathology and laboratory medicine into a world-class...
Expert Point of View: Shannon N. Westin, MD, MPH, FACOG and Alexander Melamed, MD, MPH
Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between P53 and WEE1 an “opportunity for synthetic lethality.” She continued:...
